| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Other Events
Arcus Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwrite... |
| 21 Oct 2026 |
8-K: Results of Operations and Financial Condition
Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the “Company”) as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and marketable securit... |
| 20 Oct 2026 |
8-K: Other Events
On October 20, 2026, Arcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (“ccRCC”). Th... |
| 05 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 05 May 2026 | 8-K: Results of Operations and Financial Condition |
| 20 Apr 2026 | 8-K: Other Events |
| 23 Mar 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 25 Feb 2026 | 8-K: Results of Operations and Financial Condition |
| 18 Dec 2025 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation |
| 12 Dec 2025 | 8-K: Other Events |
| 03 Nov 2025 | 8-K: Other Events |
| 28 Oct 2025 | 8-K: Results of Operations and Financial Condition |
| 14 Oct 2025 | 8-K: Other Events |
| 06 Oct 2025 | 8-K: Other Events |
| 06 Aug 2025 | 8-K: Results of Operations and Financial Condition |
| 12 Jun 2025 | 8-K: Submission of Matters to a Vote of Security Holders; Other Events |
| 02 Jun 2025 | 8-K: Regulation FD Disclosure; Other Events |
| 06 May 2025 | 8-K: Results of Operations and Financial Condition |
| 25 Feb 2025 | 8-K: Results of Operations and Financial Condition |
Loading...
